Article

FDA reviewing ophthalmic laser

San Clemente, CA—Biolase Technology Inc. says the FDA is reviewing its 510(k) regulatory submission to obtain marketing clearance for the Oculase MD laser for use in ophthalmology and oculoplasty.

San Clemente, CA-Biolase Technology Inc. says the FDA is reviewing its 510(k) regulatory submission to obtain marketing clearance for the Oculase MD laser for use in ophthalmology and oculoplasty.

The company said it aims to market the laser for general tissue ablation, anterior capsulotomy (cataract removal), skin resurfacing, and the treatment of wrinkles around the eye and orbit. Biolase Technology designs, manufactures, and markets proprietary dental laser systems, including a system that uses water and a laser to cut hard and soft dental tissues.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.